![Jin Kang Wang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jin Kang Wang
Direttore Tecnico/Scientifico/R&S presso BIOMICS BIOPHARMA LTD
Posizioni attive di Jin Kang Wang
Società | Posizione | Inizio | Fine |
---|---|---|---|
BIOMICS BIOPHARMA LTD | Direttore Tecnico/Scientifico/R&S | 01/01/2008 | - |
Biomics Biotechnologies Co., Ltd.
![]() Biomics Biotechnologies Co., Ltd. BiotechnologyHealth Technology Biomics Biotechnologies Co., Ltd. develops ribonucleic acid interference based treatment products. Its products offer treatments for Age-related Macular Degeneration (AMD), Hepatitis B, bladder cancer, and other diseases. The company was founded by York Yuan Zhu on February 17, 2006 and is headquartered in Nantong, China. | Direttore Tecnico/Scientifico/R&S | 01/01/2008 | - |
Storia della carriera di Jin Kang Wang
Precedenti posizioni note di Jin Kang Wang
Società | Posizione | Inizio | Fine |
---|---|---|---|
Valentis, Inc.
![]() Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Direttore Tecnico/Scientifico/R&S | - | - |
NeoPharm, Inc.
![]() NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Direttore Tecnico/Scientifico/R&S | - | - |
Genteric, Inc.
![]() Genteric, Inc. Pharmaceuticals: MajorHealth Technology Genteric, Inc. develops revolutionary therapeutic protein delivery technology. It is a biotech company formed to commercialize several proprietary technology platforms that harness the body's own protein production and distribution system. Genteric proprietary technology captures natural protein manufacturing capability for therapeutic benefit. The company is headquartered in Redwood City, CA. | Direttore Tecnico/Scientifico/R&S | - | - |
ALZA CORPORATION | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Jin Kang Wang
Beijing Normal University | Undergraduate Degree |
Marquette University | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Cina | 3 |
Australia | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 6 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 6 |
Consumer Services | 3 |
Process Industries | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
BIOMICS BIOPHARMA LTD | Process Industries |
Aziende private | 5 |
---|---|
Biomics Biotechnologies Co., Ltd.
![]() Biomics Biotechnologies Co., Ltd. BiotechnologyHealth Technology Biomics Biotechnologies Co., Ltd. develops ribonucleic acid interference based treatment products. Its products offer treatments for Age-related Macular Degeneration (AMD), Hepatitis B, bladder cancer, and other diseases. The company was founded by York Yuan Zhu on February 17, 2006 and is headquartered in Nantong, China. | Health Technology |
ALZA Corp.
![]() ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
NeoPharm, Inc.
![]() NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
Genteric, Inc.
![]() Genteric, Inc. Pharmaceuticals: MajorHealth Technology Genteric, Inc. develops revolutionary therapeutic protein delivery technology. It is a biotech company formed to commercialize several proprietary technology platforms that harness the body's own protein production and distribution system. Genteric proprietary technology captures natural protein manufacturing capability for therapeutic benefit. The company is headquartered in Redwood City, CA. | Health Technology |
Valentis, Inc.
![]() Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
- Borsa valori
- Insiders
- Jin Kang Wang
- Esperienza